357

S-11-B-2b

Effects

of Granulocyte-Colony-Stimulating Neutropenic

F.-D.

GOEBEL,

Poliklinik,

8000

2,

MUnchen

I.

J. R.BOGNER, and

and

Universitat

is to

of

(1,2,3).

the

only

MUnchen,

the

life

(DHPG)

disease

colony-stimulating

factor

(G-CSF)

cytes

stimulation

poesis

selective

(5). (5). We performed

study

for

6

neutropenia

on

STUDY

a

AIDS

in

In

both

the

were

in

treated

Granulocyte-

number

cells

of

of the

granulo-

granulo-

dose-escalating 10

patients

with use

for

neutropenia

therapy. the

stem

incidence

required

regimen

of

been

HIV-infected

is

placebo-controlled,

compassionate

patients In

the

0.5,

2.0,

5.0,

the

DHPG

group

(mean

G-CSF

with for

G-CSF.

DHPG-induced

basis.

group

granulocyte 2

count patients

G-CSF

below

each

1000/ƒÊ1

received

subcutaneously

received

5 ƒÊg/kg

G-CSF

were placebo,

for

10

for

6

days. up

In

to

117

days). in

analysis

a

AZT

patients

44

given

with

10.0 ƒÊg/kg

the

was

text

are

performed

means•}standard by

deviation.

Wilcoxon

Statisti-

test.

RESULTS Granulocytes

least

seen

both

reduce

has

DESIGN

eligible.

Values

and

increases

neutropenia

patients

which

cessation

of a

AZT-induced

Additional

out

8a,

substance,

treatment

(4). for

III,

Pettenkoferstr.

infections

cause

by

common

span

opportunistic

induced

most

antiviral

Gancyclovir

cytomegalovirus is

the

increase

complications

patients

cal

U.KRONAWITTER

INTRODUCTION

demonstrated

days

A. MATUSCHKE,

Germany

Azidothymidin

II.

in

AIDS-Patients

B. HEINRICH,

Medizinische

Factor

to

increased levels

dose

allowing

reduction.

under

G-CSF,

the

186/41

before

in

mean

Eight granulocyte

the

patients

treated

continuation In

placebo.

all

injection

the

AZT hours count to

of group

no

after

the

3811•}2205/41

basic

increased

first

G-CSF

at

therapy

significant the

had

with

with-

change

was

injection from (p